Life Sci Cos. Should Prep For Enforcement After COVID Pause

By John Cunningham, Linda Reig and George Karavetsos (August 10, 2021, 5:57 PM EDT) -- After hitting pause on anything not related to COVID-19 for more than a year and transitioning to a new administration in Washington, D.C., the U.S. Food and Drug Administration and other enforcement agencies are starting to return to their pre-COVID-19 agendas by, among other things, targeting compliance violations in the life sciences industry.

Since the beginning of the pandemic, the FDA has largely been preoccupied with vaccines, therapeutics and the online marketing of COVID-19-related products.[1] With most of the administration's resources allocated to responding to the pandemic, the amount of attention paid to other areas of the life sciences industry decreased...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!